title: Immunization status in children with inflammatory bowel disease.
abstract: Inflammatory bowel diseases have an increased risk of infections due to immunosuppressive therapies. To report the immunization status according to previous recommendations and the reasons explaining a delay, a questionnaire was filled in by the pediatric gastroenterologist, concerning outpatients, in six tertiary centers and five local hospitals, in a study, from May to November 2011. One hundred and sixty-five questionnaires were collected, of which 106 Crohn's diseases, 41 ulcerative colitis, and 17 indeterminate colitis. Sex ratio was 87:78 M/F. Median age was 14.4 years old (4.2-20.0). One hundred and nine patients (66 %) were receiving or had received an immunosuppressive therapy (azathioprine, infliximab, methotrexate, or prednisone). Vaccines were up to date according to the vaccine schedule of French recommendations in 24 % of cases and according to the recommendations for inflammatory bowel disease in 4 % of cases. Coverage by vaccine was the following: diphtheria-tetanus-poliomyelitis 87 %, hepatitis B 38 %, pneumococcus 32 %, and influenza 22 %. Immunization delay causes were as follows: absence of proposal 58 %, patient refusal 41 %, fear of side effects 33 %, and fear of disease activation 5 %. Therefore, immunization coverage is insufficient in children with inflammatory bowel disease, due to simple omission or to refusal. A collaboration with the attending physicians and a targeted information are necessary.
authors.affiliation: Department of Pediatrics, South Hospital, CHU Rennes, 16 Boulevard de Bulgarie, BP 90347, 35203, Rennes, Cedex, France, romain.longuet@chu-rennes.fr.
authors.forename: Romain
authors.initials: R
authors.lastname: Longuet
authors.forename: Stephanie
authors.initials: S
authors.lastname: Willot
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Giniès
authors.forename: Cecile
authors.initials: C
authors.lastname: Pélatan
authors.forename: Estelle
authors.initials: E
authors.lastname: Breton
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Segura
authors.forename: Laure
authors.initials: L
authors.lastname: Bridoux
authors.forename: Gaelle
authors.initials: G
authors.lastname: Le Henaff
authors.forename: Benoit
authors.initials: B
authors.lastname: Cagnard
authors.forename: Agathe
authors.initials: A
authors.lastname: Jobert
authors.forename: Joël
authors.initials: J
authors.lastname: Cardonna
authors.forename: Isabelle
authors.initials: I
authors.lastname: Grimal
authors.forename: Martine
authors.initials: M
authors.lastname: Balençon
authors.forename: Estelle
authors.initials: E
authors.lastname: Darviot
authors.forename: Nadège
authors.initials: N
authors.lastname: Delaperrière
authors.forename: Dominique
authors.initials: D
authors.lastname: Caldari
authors.forename: Hugues
authors.initials: H
authors.lastname: Piloquet
authors.forename: Alain
authors.initials: A
authors.lastname: Dabadie
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D005602:France; D006801:Humans; D007114:Immunization / Q000706:statistics & numerical data*; D007115:Immunization Schedule; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000276:immunology*; D008297:Male; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents